SK121697A3 - 17-difluoromethylene-oestratrienes, method of producing the same and pharmaceutical composition containing the same - Google Patents
17-difluoromethylene-oestratrienes, method of producing the same and pharmaceutical composition containing the same Download PDFInfo
- Publication number
- SK121697A3 SK121697A3 SK1216-97A SK121697A SK121697A3 SK 121697 A3 SK121697 A3 SK 121697A3 SK 121697 A SK121697 A SK 121697A SK 121697 A3 SK121697 A3 SK 121697A3
- Authority
- SK
- Slovakia
- Prior art keywords
- difluoromethylene
- estra
- hydrogen atom
- methyl
- trien
- Prior art date
Links
- BSGPCYMUVXVZHZ-DCTDBFQOSA-N (9r,10s,13s)-17-(difluoromethylidene)-13-methyl-2,3,4,5,9,10,11,12-octahydro-1h-cyclopenta[a]phenanthrene Chemical class C([C@@H]1[C@H]2CC3)CCCC1C=CC2=C1[C@@]3(C)C(=C(F)F)C=C1 BSGPCYMUVXVZHZ-DCTDBFQOSA-N 0.000 title claims abstract description 18
- 238000000034 method Methods 0.000 title claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 title claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 29
- 150000001875 compounds Chemical class 0.000 claims abstract description 22
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 13
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 6
- 125000001424 substituent group Chemical group 0.000 claims abstract description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 14
- -1 17-difluoromethylene-8a-estra-1,3,5 (10) -trien-3-ol 17-difluoromethylene-3-methoxy-18-methyl-estra-1,3,5 (10) -triene Chemical compound 0.000 claims description 10
- BWWJPRJTQKEZQL-UHFFFAOYSA-N [difluoromethyl(phenyl)phosphoryl]benzene Chemical compound C=1C=CC=CC=1P(=O)(C(F)F)C1=CC=CC=C1 BWWJPRJTQKEZQL-UHFFFAOYSA-N 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 125000006239 protecting group Chemical group 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- RXMODRJZPOLGAW-JEWRLFTDSA-N (8s,9s,13s,14s)-17-(difluoromethylidene)-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-ol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=C(F)F)[C@@H]4[C@@H]3CCC2=C1 RXMODRJZPOLGAW-JEWRLFTDSA-N 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- VVFGLBKYBBUTRO-UHFFFAOYSA-N 1-[difluoromethyl(ethoxy)phosphoryl]oxyethane Chemical compound CCOP(=O)(C(F)F)OCC VVFGLBKYBBUTRO-UHFFFAOYSA-N 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- IODAWLSYSGQMSN-WWNBULGVSA-N (8s,9s,13s,14s)-17-(difluoromethylidene)-13-ethyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-ol Chemical compound OC1=CC=C2[C@H]3CC[C@](CC)(C(CC4)=C(F)F)[C@@H]4[C@@H]3CCC2=C1 IODAWLSYSGQMSN-WWNBULGVSA-N 0.000 claims description 3
- 239000000010 aprotic solvent Substances 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 abstract description 7
- 230000000500 vasculoprotective effect Effects 0.000 abstract description 6
- 239000003963 antioxidant agent Substances 0.000 abstract description 5
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 150000003431 steroids Chemical class 0.000 abstract description 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 135
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 80
- 239000000243 solution Substances 0.000 description 74
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 54
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 54
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 37
- 239000011541 reaction mixture Substances 0.000 description 31
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 28
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 28
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 27
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 27
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 27
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- 239000000741 silica gel Substances 0.000 description 23
- 229910002027 silica gel Inorganic materials 0.000 description 23
- 239000013078 crystal Substances 0.000 description 21
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 18
- 108010007622 LDL Lipoproteins Proteins 0.000 description 17
- 102000007330 LDL Lipoproteins Human genes 0.000 description 17
- 230000003647 oxidation Effects 0.000 description 17
- 238000007254 oxidation reaction Methods 0.000 description 17
- 229910052938 sodium sulfate Inorganic materials 0.000 description 17
- 235000011152 sodium sulphate Nutrition 0.000 description 17
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 16
- 239000000725 suspension Substances 0.000 description 15
- 239000000203 mixture Substances 0.000 description 14
- 235000017557 sodium bicarbonate Nutrition 0.000 description 14
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 14
- 230000008020 evaporation Effects 0.000 description 10
- 238000001704 evaporation Methods 0.000 description 10
- 235000006408 oxalic acid Nutrition 0.000 description 9
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 8
- 210000003038 endothelium Anatomy 0.000 description 8
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 8
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 7
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000009471 action Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000010949 copper Substances 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- RXMODRJZPOLGAW-DRMAHVMPSA-N (8r,9s,13s,14s)-17-(difluoromethylidene)-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-ol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=C(F)F)[C@@H]4[C@H]3CCC2=C1 RXMODRJZPOLGAW-DRMAHVMPSA-N 0.000 description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 210000000709 aorta Anatomy 0.000 description 4
- 229910052802 copper Inorganic materials 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 229960005309 estradiol Drugs 0.000 description 4
- 229930182833 estradiol Natural products 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 4
- 238000010626 work up procedure Methods 0.000 description 4
- QOSNUXWKMAFZHA-FSPQTFJISA-N (8s,9s,13s,14s)-13-methyl-3-(oxan-2-yloxy)-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-17-one Chemical compound C([C@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CCC4=O)C)CC2=CC=3OC1CCCCO1 QOSNUXWKMAFZHA-FSPQTFJISA-N 0.000 description 3
- WXLOHLKQCCSUCU-KOKLOHSUSA-N 2-[[(8r,9s,13s,14s)-17-(difluoromethylidene)-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-yl]oxy]oxane Chemical compound C([C@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CCC4=C(F)F)C)CC2=CC=3OC1CCCCO1 WXLOHLKQCCSUCU-KOKLOHSUSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 230000001196 vasorelaxation Effects 0.000 description 3
- WAPPBJJZTZBGQW-WIRSXHRWSA-N (8s,9s,13s,14s)-17-(difluoromethylidene)-13-ethyl-3-methoxy-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene Chemical compound COC1=CC=C2[C@H]3CC[C@](CC)(C(CC4)=C(F)F)[C@@H]4[C@@H]3CCC2=C1 WAPPBJJZTZBGQW-WIRSXHRWSA-N 0.000 description 2
- WXLOHLKQCCSUCU-QIPUZLNJSA-N 2-[[(8s,9s,13s,14s)-17-(difluoromethylidene)-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-yl]oxy]oxane Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CCC4=C(F)F)C)CC2=CC=3OC1CCCCO1 WXLOHLKQCCSUCU-QIPUZLNJSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010047163 Vasospasm Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 229910000365 copper sulfate Inorganic materials 0.000 description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 102000015694 estrogen receptors Human genes 0.000 description 2
- 108010038795 estrogen receptors Proteins 0.000 description 2
- 210000000540 fraction c Anatomy 0.000 description 2
- BCDGQXUMWHRQCB-UHFFFAOYSA-N glycine methyl ketone Natural products CC(=O)CN BCDGQXUMWHRQCB-UHFFFAOYSA-N 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 2
- 229960001802 phenylephrine Drugs 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- SONVSJYKHAWLHA-HTWSVDAQSA-N (13s)-3-hydroxy-13-methyl-7,8,12,14,15,16-hexahydro-6h-cyclopenta[a]phenanthren-17-one Chemical compound OC1=CC=C2C3=CC[C@](C)(C(CC4)=O)C4C3CCC2=C1 SONVSJYKHAWLHA-HTWSVDAQSA-N 0.000 description 1
- OUGSRCWSHMWPQE-WMZOPIPTSA-N (13s,14s)-3-hydroxy-13-methyl-7,11,12,14,15,16-hexahydro-6h-cyclopenta[a]phenanthren-17-one Chemical compound OC1=CC=C2C(CC[C@]3([C@H]4CCC3=O)C)=C4CCC2=C1 OUGSRCWSHMWPQE-WMZOPIPTSA-N 0.000 description 1
- FHJVQLWFUQMADH-XSYGEPLQSA-N (8r,9s,13s,14s)-13-ethyl-3-methoxy-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-17-one Chemical compound COC1=CC=C2[C@H]3CC[C@](CC)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 FHJVQLWFUQMADH-XSYGEPLQSA-N 0.000 description 1
- QOSNUXWKMAFZHA-TYZGACFUSA-N (8r,9s,13s,14s)-13-methyl-3-(oxan-2-yloxy)-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-17-one Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CCC4=O)C)CC2=CC=3OC1CCCCO1 QOSNUXWKMAFZHA-TYZGACFUSA-N 0.000 description 1
- NJSCJHMZMZOGDE-VXNCWWDNSA-N (8r,9s,13s,14s)-3-methoxy-13-methyl-7,8,9,11,12,14-hexahydro-6h-cyclopenta[a]phenanthren-17-one Chemical compound C1C[C@]2(C)C(=O)C=C[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 NJSCJHMZMZOGDE-VXNCWWDNSA-N 0.000 description 1
- SKOXKCJAYXLNPS-FVMPEHLCSA-N (8s,9s,11s,13s,14s)-17-(difluoromethylidene)-11-methoxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-ol Chemical compound OC1=CC=C2[C@H]3[C@@H](OC)C[C@]4(C)C(=C(F)F)CC[C@H]4[C@@H]3CCC2=C1 SKOXKCJAYXLNPS-FVMPEHLCSA-N 0.000 description 1
- DNXHEGUUPJUMQT-CVYDXHPNSA-N (8s,9s,13s,14s)-3-hydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-17-one Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@H]3CCC2=C1 DNXHEGUUPJUMQT-CVYDXHPNSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- WTRRIQCGCGCMQA-CBZIJGRNSA-N 3-Hydroxyestra-1,3,5(10),6-tetraen-17-one Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3C=CC2=C1 WTRRIQCGCGCMQA-CBZIJGRNSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- DLDIKZAXLWSUNZ-DCTDBFQOSA-N C[C@]1(CC[C@H]2C3=CCC4[C@@H]2CCCC4)C3=CC=C1C(F)F Chemical class C[C@]1(CC[C@H]2C3=CCC4[C@@H]2CCCC4)C3=CC=C1C(F)F DLDIKZAXLWSUNZ-DCTDBFQOSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- WKRLQDKEXYKHJB-UHFFFAOYSA-N Equilin Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3=CCC2=C1 WKRLQDKEXYKHJB-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- ODUCDPQEXGNKDN-UHFFFAOYSA-N Nitrogen oxide(NO) Natural products O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000006906 Vascular Ring Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical compound CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N diisobutylaluminium hydride Substances CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- WKRLQDKEXYKHJB-HFTRVMKXSA-N equilin Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 WKRLQDKEXYKHJB-HFTRVMKXSA-N 0.000 description 1
- 150000002164 estratrienes Chemical class 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- 210000002196 fr. b Anatomy 0.000 description 1
- 210000003918 fraction a Anatomy 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- OVEHNNQXLPJPPL-UHFFFAOYSA-N lithium;n-propan-2-ylpropan-2-amine Chemical compound [Li].CC(C)NC(C)C OVEHNNQXLPJPPL-UHFFFAOYSA-N 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Electrical Control Of Air Or Fuel Supplied To Internal-Combustion Engine (AREA)
- Exhaust-Gas Circulating Devices (AREA)
- Photoreceptors In Electrophotography (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Ceramic Products (AREA)
- Vehicle Body Suspensions (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19509729A DE19509729A1 (de) | 1995-03-13 | 1995-03-13 | 17-Difluormethylen-Estratriene |
| PCT/EP1996/001069 WO1996028462A1 (de) | 1995-03-13 | 1996-03-13 | 17-difluormethylen-estratriene |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK121697A3 true SK121697A3 (en) | 1998-02-04 |
Family
ID=7756963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1216-97A SK121697A3 (en) | 1995-03-13 | 1996-03-13 | 17-difluoromethylene-oestratrienes, method of producing the same and pharmaceutical composition containing the same |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US6018062A (de) |
| EP (1) | EP0815120B1 (de) |
| JP (1) | JPH11501644A (de) |
| KR (1) | KR19980703002A (de) |
| AT (1) | ATE199159T1 (de) |
| AU (1) | AU693335B2 (de) |
| BR (1) | BR9612787A (de) |
| CA (1) | CA2215201A1 (de) |
| CZ (1) | CZ281097A3 (de) |
| DE (2) | DE19509729A1 (de) |
| HU (1) | HUP9801846A3 (de) |
| IL (1) | IL117497A (de) |
| IS (1) | IS4556A (de) |
| NO (1) | NO308306B1 (de) |
| PL (1) | PL322199A1 (de) |
| RU (1) | RU2155770C2 (de) |
| SI (1) | SI9620030A (de) |
| SK (1) | SK121697A3 (de) |
| TR (1) | TR199700950T1 (de) |
| WO (1) | WO1996028462A1 (de) |
| ZA (1) | ZA962037B (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU703814B2 (en) * | 1995-12-04 | 1999-04-01 | Wyeth | Antioxidant |
| US5773432A (en) * | 1996-10-30 | 1998-06-30 | Schering Aktiengesellschaft | Method for lowering plasma levels of lipoprotein(a) |
| CN1820056A (zh) * | 2003-08-11 | 2006-08-16 | 雷吉亚纳化学工业有限公司 | 用于车体修理的化学组合物及其聚合方法 |
| EP1789056A1 (de) * | 2004-06-29 | 2007-05-30 | Jado Technologies GmbH | Verwendung von pharmazeutischen zusammensetzungen von steroiden zur behandlung von erkrankungen im zusammenhang mit pathologischen prozessen in lipid-rafts |
| US8030298B2 (en) | 2005-05-26 | 2011-10-04 | Abbott Products Gmbh | 17β-HSD1 and STS inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3741800A1 (de) * | 1987-12-07 | 1989-06-15 | Schering Ag | 17-halogenmethylen-estratriene |
| US5969168A (en) * | 1991-01-07 | 1999-10-19 | Pherin Corporation | Androstanes for inducing hypothalamic effects |
| US5883087A (en) * | 1991-01-07 | 1999-03-16 | Pherin Corporation | Androstane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods |
| US5783571A (en) * | 1991-01-07 | 1998-07-21 | Pherin Corporation | Method of altering hypothalamic function by nasal administration of estrene steroids |
| US5773432A (en) * | 1996-10-30 | 1998-06-30 | Schering Aktiengesellschaft | Method for lowering plasma levels of lipoprotein(a) |
-
1995
- 1995-03-13 DE DE19509729A patent/DE19509729A1/de not_active Withdrawn
-
1996
- 1996-03-13 AU AU51078/96A patent/AU693335B2/en not_active Ceased
- 1996-03-13 CA CA002215201A patent/CA2215201A1/en not_active Abandoned
- 1996-03-13 EP EP96907453A patent/EP0815120B1/de not_active Expired - Lifetime
- 1996-03-13 AT AT96907453T patent/ATE199159T1/de not_active IP Right Cessation
- 1996-03-13 JP JP8527276A patent/JPH11501644A/ja active Pending
- 1996-03-13 HU HU9801846A patent/HUP9801846A3/hu unknown
- 1996-03-13 PL PL96322199A patent/PL322199A1/xx unknown
- 1996-03-13 KR KR1019970706410A patent/KR19980703002A/ko not_active Application Discontinuation
- 1996-03-13 BR BR9612787-2A patent/BR9612787A/pt not_active Application Discontinuation
- 1996-03-13 SK SK1216-97A patent/SK121697A3/sk unknown
- 1996-03-13 ZA ZA962037A patent/ZA962037B/xx unknown
- 1996-03-13 TR TR97/00950T patent/TR199700950T1/xx unknown
- 1996-03-13 DE DE59606435T patent/DE59606435D1/de not_active Expired - Fee Related
- 1996-03-13 SI SI9620030A patent/SI9620030A/sl unknown
- 1996-03-13 WO PCT/EP1996/001069 patent/WO1996028462A1/de not_active Application Discontinuation
- 1996-03-13 RU RU97116513/04A patent/RU2155770C2/ru active
- 1996-03-13 US US08/913,325 patent/US6018062A/en not_active Expired - Fee Related
- 1996-03-13 CZ CZ972810A patent/CZ281097A3/cs unknown
- 1996-03-14 IL IL11749796A patent/IL117497A/xx not_active IP Right Cessation
-
1997
- 1997-09-08 IS IS4556A patent/IS4556A/is unknown
- 1997-09-12 NO NO974206A patent/NO308306B1/no unknown
-
1999
- 1999-03-08 US US09/263,062 patent/US6136800A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP0815120A1 (de) | 1998-01-07 |
| WO1996028462A1 (de) | 1996-09-19 |
| CZ281097A3 (cs) | 1998-02-18 |
| PL322199A1 (en) | 1998-01-19 |
| RU2155770C2 (ru) | 2000-09-10 |
| NO974206D0 (no) | 1997-09-12 |
| AU5107896A (en) | 1996-10-02 |
| SI9620030A (sl) | 1998-02-28 |
| MX9707006A (es) | 1997-11-29 |
| DE59606435D1 (de) | 2001-03-22 |
| JPH11501644A (ja) | 1999-02-09 |
| IS4556A (is) | 1997-09-08 |
| US6136800A (en) | 2000-10-24 |
| CA2215201A1 (en) | 1996-09-19 |
| IL117497A0 (en) | 1996-07-23 |
| HUP9801846A3 (en) | 1999-03-01 |
| NO974206L (no) | 1997-11-13 |
| US6018062A (en) | 2000-01-25 |
| DE19509729A1 (de) | 1996-09-19 |
| HUP9801846A2 (hu) | 1998-12-28 |
| KR19980703002A (ko) | 1998-09-05 |
| IL117497A (en) | 1999-12-22 |
| EP0815120B1 (de) | 2001-02-14 |
| NO308306B1 (no) | 2000-08-28 |
| ZA962037B (en) | 1996-09-25 |
| BR9612787A (pt) | 1999-11-23 |
| TR199700950T1 (xx) | 1998-02-21 |
| AU693335B2 (en) | 1998-06-25 |
| ATE199159T1 (de) | 2001-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100333151B1 (ko) | 단량체성담즙산유도체 | |
| US5512558A (en) | Nor-bile acid derivatives, processes for their preparation and the use of these compounds as medicaments | |
| US4235893A (en) | Ester derivatives of 4-hydroxy-4-androstene-3,17-dione and a method for inhibiting estrogen biosynthesis | |
| RU2186781C2 (ru) | Нитроэфиры кортикоидных соединений | |
| US4921848A (en) | Biliary acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them | |
| CA1123739A (en) | 15-oxygenated sterol compounds and the use of such compounds to inhibit the biosynthesis of sterols | |
| JP2724114B2 (ja) | トリテルペン誘導体およびそれを含有するエンドセリンレセプター拮抗剤 | |
| US4885280A (en) | Novel 14-amino steroids | |
| US5116829A (en) | Steroid compounds | |
| US5144017A (en) | Compounds that bind to digitalis receptor | |
| JPS6119640B2 (de) | ||
| US4882315A (en) | Aminoglycoside steroids, a process for their preparation, their use and pharmaceutical compositions containing them | |
| DE4338316A1 (de) | Neue Steroide mit radikophilen Substituenten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| US4588530A (en) | Anti-inflammatory prednisolone steroids | |
| SK121697A3 (en) | 17-difluoromethylene-oestratrienes, method of producing the same and pharmaceutical composition containing the same | |
| EP0056000B1 (de) | 17-(Alkoxycarbonyl)(formamid)methylen-Steroidderivate und ihre Herstellung | |
| FI92706C (fi) | Menetelmä 19-hydroksylaasi-inhibiittoreina käyttökelpoisten 19-substituoitujen progesteronijohdannaisten valmistamiseksi | |
| Smith et al. | Cardenolide analogs. 14. Synthesis and biological activity of glucosides of 17. beta.-modified derivatives of digitoxigenin | |
| JPH08269063A (ja) | ピリピロペン誘導体 | |
| US4648995A (en) | Chemical synthesis | |
| Templeton et al. | Cardiac glycoside-like structure and function of 5. beta., 14. beta.-pregnanes | |
| US6274559B1 (en) | Liver protection or treatment agents comprising asiatic acid derivatives as the active component | |
| MXPA97007006A (en) | 17-difluorometil stratrenes | |
| US4329295A (en) | 24-Cyclopropylcholene-3β, 22-diols and esters thereof | |
| US4510323A (en) | Cis-bicyclo[3.3.0]octane derivatives, medicaments containing them and processes for their preparation and use |